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in the PBSC product, we used a combination of CD34 selection
and ex vivo incubation with anti-CD3 antibody, which resulted in
a mean 5.2-log reduction of T cells (range, 4.7–6.3 log). The ﬁnal
PBSC products contained a mean of 9.94 (range, 4.8–13.0)  106
CD34 cells/kg and 1.34 (range, 0.06–4.54)  103 CD3 cells/
kg. The daily dose of CY was 200 mg/m2 in the ﬁrst 3 patients and
400 mg/m2 in the next 2 patients. The mean half-life (t1/2) of
CD3 cells in these patients was biphasic: 0.8 days from day7 to
day5 and 0.2 days from day5 to day3, correlating with ATG
administration. In contrast, the mean t1/2 of CD3 cells was 2.5
days in patients with hematologic malignancies receiving a myeloa-
blative preparative regimen of CY, busulfan, and etoposide. After
PBSCT, the median nadirs of WBC, ANC, and platelets were 1.2
(range, 0.4–2.0), 0.9 (range, 0.1–1.7) and 135 (range, 114–185) 
109/L, respectively. All patients are alive at a median of 8.5
months (range, 6.9 to 17.5 months) after PBSCT. Compared
with pre-PBSCT levels, Rodnan total skin score (TSS) decreased
by 4, 10, 11, and 15 points, respectively, in 4 patients and increased
by 8 points in 1 patient, who also developed SSc renal crisis
requiring hemodialysis at 12 months after PBSCT. Of 4 patients
with improved TSS, 1 has worsening polymyositis and 1 has
recurrence of palpable tendon friction rubs. Even at the lowest CY
dose, this immunosuppressive regimen provides signiﬁcantly
greater and more rapid T-cell kill than a conventional myeloabla-
tive regimen. The efﬁcacy of this regimen and TCD PBSCT in
SSc is encouraging. but requires longer follow-up and experience
with a larger number of patients.
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CONSOLIDATION AND MOBILIZATION OF PERIPHERAL BLOOD STEM
CELLS USING HIGH-DOSE CYTARABINE AND ETOPOSIDE IN ACUTE
MYELOID LEUKEMIA: A SINGLE INSTITUTIONAL EXPERIENCE
Shu, F., Bashey, A., Carrier, E., Castro, J., Holman, P., Lane, T.,
Medina, B., Corringham, S., Ball, E.D. Division of Blood and Marrow
Transplantation, Department of Medicine, and Moores’ UCSD Cancer
Center, University of California at San Diego, La Jolla, CA.
Autologous hematopoietic stem cell transplantation (autoHSCT)
as consolidation in ﬁrst complete remission (CR1) is an option for
patients with AML. Achieving adequate numbers of stem cells and
eradicating residual leukemia cells with acceptable toxicity repre-
sent two conﬂicting goals. Between May 2000 and May 2004, we
performed autoHSCT in 24 AML patients using a reduced dose
modiﬁcation of a cytarabine/etoposide regimen reported by Linker
(BBMT 6:50–57, 2000) as a consolidation and stem cell mobiliza-
tion regimen. Median age at the time of HSCT was 59 (range,
21–73; 50%  60 years). Most patients had intermediate-risk
(63%) or high-risk cytogenetics (25%). All patients but 1 were in
CR1 before autoHSCT. After induction chemotherapy, 12 pa-
tients proceeded to consolidation/mobilization. Twleve patients
had additional consolidation with cytarabine-based regimens (8
with 1 consolidation and 4 with 2 consolidations). All patients then
received etoposide (5 mg/kg IV every 12 hours) and cytarabine (2
g/m2 IV every 12 hours) for 3 days instead of the 4 days described
by Linker. Patients received G-CSF (10 g/kg SC) on day 14 until
the WBC count was 10,000. The median number of CD34
stem cells collected was 5.9  106/kg (range, 1.3–75.5). Some 92%
of patients received busulfan and cyclophosphamide as a condi-
tioning regimen. There were no treatment-related deaths. En-
graftment was rapid: WBC 1000 in 11.5 days (range, 9–19 days),
ANC 500 in 12 days (range, 10–21 days), and platelets 50,000
in 17 days (range, 11–214 days). Median follow-up is 13.6 months
(range, 2–52 months). Eleven patients (46%) relapsed at a median
of 5.4 months (range 1.2–27.5 months). Median disease-free sur-
vival (DFS) for all patients is 27.5 months. Patients with interme-
diate- and high-risk cytogenetics had a 1-year DFS of 54% and
50%, respectively. Patients receiving at least 1 consolidation before
the mobilization regimen had 1-year DFS and overall survival (OS)
of 56% and 73%, respectively compared with 46% and 64% for
those proceeding directly from induction to mobilization. Our data
suggest that autoHSCT using reduced doses of cytarabine and
etoposide as a consolidation and mobilization regimen is safe and
effective at achieving engraftment, and is associated with encour-
aging outcomes in patients with intermediate- to high-risk cyto-
genetics. At least 1 consolidation before the mobilization/consoli-
dation regimen may be associated with superior outcome.
Prospective trials with larger numbers of patients are needed to
validate our preliminary ﬁndings.
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PEDIATRIC SOLID TUMORS
Fraser, C.J.1, Weigel, B.J.1, John, P.P.2, Todd, D.E.1, Kevin, B.S.1,
Michael, V.R.1 1University of Minnesota, Minneapolis, MN; 2Cincin-
nati Children’s Hospital Medical Center, Cincinnati, OH.
Aim: The purpose of this study was to determine the toxicity of
treatment with high-dose alkylating agents followed by ASCT, to
monitor treatment response and to promote disease free survival in
a group of pediatric patients with high risk solid tumors.Methods:
A total of 36 patients with solid tumors having disseminated disease
at diagnosis or following relapse were treated on 2 consecutive
autologous transplantation protocols at the University of Minne-
sota between May 1995 and March 2004. Preliminary data on 11 of
these patients have already been reported. The age range of the
patients was 2–26 years. Of the 36 patients, 20 had a diagnosis of
a Ewing’s family tumor (16 Ewing’s sarcoma and 4 desmoplastic
small round cell tumor). Other diagnoses included rhabdomyosar-
coma (in 3 patients), Wilm’s tumor (in 2), medulloblastoma (in 2),
and ependymoma, atypical teratoid rhabdoid tumor, glioblastoma
multiforme, osteosarcoma, hepatoblastoma, retinoblastoma, cervi-
cal chordoma, ovarian small cell carcinoma and ovarian mixed
anaplastic germ cell tumor each in 1 patient. Patients were eligible
for transplantation if they had a complete response (CR) (18
patients) or a very good partial response with nonprogressive
disease (18 patients). Conditioning therapy consisted of either oral
busulfan (12 mg/kg) or intravenous busulfan (9.6 mg/kg  4 years;
12 mg/kg  4 years), melphalan (100 mg/m2) and thiotepa (500
mg/m2). Thirteen patients received the chemoprotectant amifos-
tine. All patients received G-CSF until neutrophil engraftment.
Twenty patients received PBSC, 15 patients received autologous
bone marrow, and 1 patient received syngeneic marrow. Results:
Median time to neutrophil engraftment, deﬁned as the ﬁrst of 3
consecutive days of an ANC  0.5  109/L, was 11 days (range,
9–56 days). Overall survival was 63% (range, 47%-79%) at 1 year
and 33% (range, 16%-50%) at 3 years. Disease-free survival was
28% (range, 13%-43%) at 3 years. Median follow-up among sur-
vivors is 3.5 years (range, 0.6–7.9 years). Three-year overall sur-
vival for Ewing’s family tumors was signiﬁcantly better than for all
other diagnoses (54% vs 13%; P .03). Three-year overall survival
was signiﬁcantly better for those patients transplanted after CR
(48% vs 12%; P  .03). There were 2 toxic deaths attributed to
veno-occlusive disease. Conclusions: Our data indicate that
ASCT after high-dose alkylating agent therapy has acceptable
toxicity and should be considered as consolidation therapy for
patients with high-risk Ewing’s family tumors. The effectiveness of
this therapy for other diagnoses appears to be limited.
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TANDEM AUTOGRAFTS FOR MULTIPLE MYELOMA PATIENTS USING
TWO DIFFERENT CONDITIONING REGIMENS: AN INTERIM ANALYSIS
Liu, H.1, Roberts, C.2, Pumphrey, P.2, Wingard, J.R.1, Moreb, J.S.1
1University of Florida College of Medicine, Gainesville, FL; 2Shands
Hospital at University of Florida, Gainesville, FL.
Autologous stem cell transplantation (ASCT) has become a stan-
dard therapy for multiple myeloma (MM) patients. In the current
study, we evaluated the toxicity and efﬁcacy of tandem autografts
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